Correlations of IL-1β and vitamin D with CAT score in patients with acute exacerbation of chronic obstructive pulmonary disease

Lidong Wang, Mai Wang, Dan Qian, Xing Ding, Heping Jiang*

Department of Respiratory and Critical Care Medicine, Changzhou Jintan First People's Hospital, Changzhou, 213200, China

**Article Info**

**Original paper**

**Article history:**
Revised: July 10, 2023
Accepted: November 13, 2023
Published: December 31, 2023

**Keywords:**
IL-1β, vitamin D, chronic obstructive pulmonary disease, receiver operating characteristic

**ABSTRACT**

This study was to analyze the correlations of IL-1β and vitamin D (VitD) with chronic obstructive pulmonary disease assessment test (CAT) score in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). For this purpose, a total of 65 patients with chronic obstructive pulmonary disease (COPD) treated in our hospital between June 2020 and June 2022 were enrolled and assigned to a research group, and 40 healthy individuals who underwent physical examination in our hospital over the same time spanning were enrolled into the control group. The 65 COPD patients were further grouped into a stability group (30 cases) and an exacerbation group (35 cases). The two groups were compared in the levels of 25-hydroxyvitamin D (25(OH)D), interleukin-1β (IL-1β) and blood gas indexes (arterial carbon dioxide partial pressure (PaCO2) and arterial partial pressure of oxygen (PaO2)). The modified Medical Research Council Dyspnea Scale (mMRC) and the CAT were adopted for evaluation of the stability group and exacerbation group. The correlations of IL-1β and 25(OH)D with mMRC and CAT scores were analyzed. The diagnostic value of IL-1β and VitD in patients in different stages was analyzed through receiver operating characteristic (ROC) curves. Results showed that the control group showed greatly lower IL-1β and PaCO2 levels and higher 25(OH)D and PaO2 levels than the research group (all P<0.05). The stability group got greatly lower mMRC and CAT scores than the exacerbation group (both P<0.05). IL-1β had positive correlations with mMRC and CAT scores, while 25(OH)D had negative correlations with them (P<0.05). According to ROC curve-based analysis, IL-1β and 25(OH)D had areas under the curves of 0.814 and 0.583, respectively, in diagnosing the acute exacerbation period, and had specificities of 56.67% and 43.33%, respectively and sensitivities of 97.14% and 74.29%, respectively. In conclusion, patients with COPD have increased IL-1β and VitD deficiency, so VitD can be properly supplemented during treatment, and the levels of inflammatory factors should be paid close attention to at all times. IL-1β and VitD can be regarded as novel ideas for the diagnosis and treatment of COPD, which may further improve the effect of COPD prevention and treatment.

**Introduction**

Chronic obstructive pulmonary disease (COPD) is a frequently-seen, preventable and treatable chronic airway inflammatory disease, with features of incomplete reversible airflow limitation and corresponding respiratory symptoms (1). Its early symptoms include repeated cough and expectoration, and even dyspnea in severe cases (2). Although the disease is an airway disease, its impact on the whole body system should not be underestimated (3). According to the statistical results, COPD afflicts approximately 100 million patients in China in 2018, with a prevalence rate of 8.6% among individuals over 20 years old and a prevalence rate of 13.7% among individuals over 40 years old, and it ranks third in the cause of death in 2020 (4). COPD has become a major disease like hypertension and diabetes mellitus, and its burden has ranked third (5). The disease can be classified into COPD at the stable stage and COPD at the acute exacerbation stage according to the disease process. The symptoms in the stable period are mild, while the clinical symptoms in the acute exacerbation period continue to deteriorate, mainly manifested as cough, expectoration, shortness of breath or wheezing, and increased sputum volume, accompanied by fever and other symptoms of aggravated inflammation.

Currently, the clinical research on acute exacerbation of COPD (AECOPD) has made progress, but there is still a lack of clear indicators for the prevention, diagnosis, treatment and prognosis of it, which may delay the optimal treatment timing (6). Therefore, it is still imperative to find appropriate associated indicators to prevent and treat patients with AECOPD, so as to effectively avoid or reduce acute attacks and achieve the optimal treatment effect. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine involved in host defense responses like immune response, inflammation, fever and acute protein synthesis, which can trigger pulmonary inflammation featured with granulocyte and macrophage infiltration in the lung (7). Reportedly, the increased IL-1β expression may be adopted as a biomarker of persistent neutrophil airway inflammation and potential persistent deterioration in COPD (8). Vitamin D (VitD) is a frequently-seen fat-soluble vitamin, with a crucial role in the growth and development of the body and cell growth and differentiation (9). Its main form is 25-hy-
droxyvitamin D (25(OH)D), which is usually adopted to evaluate the VitD level in the human body. According to prior research (10), VitD can not only regulate calcium and phosphorus metabolism, but is also bound up with respiratory system and lung function, and its deficiency may impair lung function and increase the risk of respiratory tract infection.

AECOPD does great harm to patients' life and health and will cause a series of adverse reactions, seriously compromising patients’ quality of life. Accordingly, this study explored the correlations of IL-1β and VitD with chronic obstructive pulmonary disease assessment test (CAT) scores in patients with AECOPD, to provide a reference for clinical diagnosis and treatment of the disease.

Materials and Methods

Clinical data
Totally 65 patients with COPD treated in our hospital between June 2020 and June 2022 were enrolled and assigned to a research group, and 40 healthy individuals who underwent physical examination in our hospital over the same time span were enrolled in the control group. The 65 COPD patients were further grouped into a stability group (30 cases) and an exacerbation group (35 cases). This study was performed with approval from the Medical Ethics Committee of our hospital.

Inclusion and exclusion criteria

Inclusion criteria
Patients in the research group all met the diagnostic criteria of COPD (11), and the criteria for judging the severity are shown in Table 1. Patients at the I-II stage were assigned to a stability group, and those at the III-IV stage were assigned to an exacerbation group. Individuals in the control group were all healthy individuals without any disease. All subjects voluntarily participated in this study and signed informed consent, and their clinical data were complete.

Exclusion criteria
Terminally ill patients were comorbid with malignant tumour or other diseases; patients with diabetes mellitus or heart, liver or renal failure; patients with mental disorders, patients who withdrew from the study midway, and pregnant women.

Index detection method
Fasting peripheral venous blood (6mL) was acquired from each participant, and let to stand at indoor temperature (2-4 h), followed by 20-min centrifugation (3000r/min). Then the serum was collected, and stored at low temperature for testing. 25(OH)D and IL-1β in the serum were quantified using the immunosorbent assay under strict instructions. An automatic blood gas analyzer was adopted for the determination of the blood gas indexes of each individual, including arterial carbon dioxide partial pressure (PaCO₂) and arterial partial pressure of oxygen (PaO₂).

Outcome measures
Primary outcome measures: The 25(OH)D and IL-1β levels of the two groups were compared, and the correlations of IL-1β and 25(OH)D with mMRC and CAT scores were analyzed.

Secondary outcome measures: The blood gas indexes including PaO₂, and PaCO₂, were compared between the patients and healthy individuals. The modified Medical Research Council Dyspnea Scale (mMRC) was adopted for assessment of patients’ dyspnea: 0 points: mild; 1 point: moderate; 2 points: severe; 3-4 points: extremely severe. The CAT was adopted for the self-assessment test of patients with AECOPD. The test score ranges between 0 and 40 points, with 0-10 points for slight impact, 11-20 points for moderate impact; 21-30 points for serious impact and 31-40 points for extremely serious impact.

Statistical analyses
This study adopted SPSS 20.0 (SPSS Inc., Chicago, IL, USA) for analysis of collected data, and GraphPad Prism 8 for data visualization. The data of this study were normally distributed and were analyzed via the t-test. The correlations of different variables were analyzed using the Pearson test. P<0.05 implies a notable difference.

Results

Baseline data
According to the comparison of clinical data, the control and research groups were similar in age, gender, body mass index (BMI), smoking history and drinking history (all P>0.05, Table 2).

IL-1β and VitD levels
According to the comparison of IL-1β and VitD levels between the two groups, the control group showed a greatly lower IL-1β level and a notably higher 25(OH)D level than the research group (both P<0.05, Figure 1).

Table 1. Severity grading.

<table>
<thead>
<tr>
<th>Severity grading</th>
<th>Evaluation criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I (mild)</td>
<td>FEV₁≥80% predicted value; have no obvious symptoms or mild symptoms.</td>
</tr>
<tr>
<td>Grade II (Moderate)</td>
<td>50% predicted value≤FEV₁&lt;80% predicted value; have obvious chronic cough and expectoration.</td>
</tr>
<tr>
<td>Grade III (Severe)</td>
<td>30% predicted value≤FEV₁&lt;50% predicted value; have chronic cough, expectoration, dyspnea, etc.</td>
</tr>
<tr>
<td>Grade IV (extremely severe)</td>
<td>FEV₁&lt;30% predicted value or FEV₁&lt;50% predicted value, accompanied by respiratory failure; have severe dyspnea and hypoxemia according to test results.</td>
</tr>
</tbody>
</table>

FEV₁: Forced expiratory volume in 1 second.
Table 2. Baseline data.

<table>
<thead>
<tr>
<th>Factors</th>
<th>Control group (n=40)</th>
<th>Research group (n=65)</th>
<th>( \chi^2 ) value</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>≤65 years old</td>
<td>23</td>
<td>31</td>
<td>0.953</td>
</tr>
<tr>
<td></td>
<td>&gt;65 years old</td>
<td>17</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>25</td>
<td>39</td>
<td>0.065</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>15</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>≤23kg/m(^2)</td>
<td>23</td>
<td>28</td>
<td>2.062</td>
</tr>
<tr>
<td></td>
<td>&gt;23kg/m(^2)</td>
<td>17</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Smoking history</td>
<td>Yes</td>
<td>22</td>
<td>36</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>18</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Drinking history</td>
<td>Yes</td>
<td>29</td>
<td>47</td>
<td>0.000</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>11</td>
<td>18</td>
<td></td>
</tr>
</tbody>
</table>

**Blood gas index levels**

According to analysis and comparison of blood gas indexes between the two groups, the control group showed a greatly higher PaO\(_2\) level and a greatly lower PaCO\(_2\) level than the research group (both \(P<0.05\), Figure 2).

**mMRC and CAT scores of the stability group and exacerbation group**

According to the analysis and comparison of mMRC and CAT scores between the stability group and exacerbation group, the stability group got greatly lower mMRC and CAT scores than the exacerbation group (both \(P<0.05\), Figure 3).

**Correlations of IL-1β and 25(OH)D with mMRC and CAT scores**

The Pearson test was carried out on the correlations of IL-1β and 25(OH)D with mMRC and CAT scores. According to the results, IL-1β had positive correlations with mMRC and CAT scores, while 25(OH)D had negative correlations with them (all \(P<0.05\), Figure 4).

**Clinical diagnostic value of IL-1β and 25(OH)D for AECOPD**

For understanding the diagnostic value of IL-1β and 25(OH)D for AECOPD, receiver operating characteristic (ROC) curves were drawn. According to ROC curve-based analysis, IL-1β and 25(OH)D had areas under the curves (AUCs) of 0.814 and 0.583, respectively, in diagnosing AECOPD, and had specificities of 56.67% and 43.33%, respectively, and sensitivities of 97.14% and 74.29%, respectively, in it (Table 3 and Figure 5).

**Discussion**

Over the past few years, COPD presents an increasing incidence and is the most frequently seen among individuals over 40 years old (12). It usually results in the progressive decline of lung function, finally increasing morta-
lity and disability, which seriously compromises the quality of life of patients. COPD is a chronic inflammatory disease of the lung, but its harm to the human body should not be underestimated (13). When the disease develops to acute exacerbation, patients will suffer more serious expectoration, asthma and dyspnea than usual, and patients in severe cases may have pulmonary heart disease and respiratory failure if they are not given timely treatment (14). According to the analysis results of patients’ blood gas indexes in this study, the control group presented a notably higher PaO₂ level and a notably lower PaCO₂ level than the research group, indicating that long-term weakening of lung function will lead to CO₂ retention and hypoxemia, and the disease aggravation during acute exacerbation will lead to severe hypoxia and respiratory failure, increasing the risk of death. According to associated research (15), during every period of AECOPD, the patients showed a more severe decline of FEV₁ than those with normal lung function, implying the side impacts of the disease on the lung function of patients. Accordingly, it is of profound significance to find suitable associated indexes for the diagnosis and treatment of COPD.

Currently, the pathogenesis of COPD is still under investigation. It is generally believed that its pathogenesis mainly involves inflammatory reactions, the imbalance between oxidation and antioxidation. Airflow restriction and airway obstruction are the most crucial pathophysiological changes in COPD cases, but the specific mechanism leading to airway and pulmonary vascular inflammation remains unclear (16). According to related research (17), patients with AECOPD and respiratory failure showed notably different levels of serum TNF-α and other inflammatory mediators before and after treatment, indicating a strong association of COPD with inflammatory mediators. IL-1β, also known as a catabolic factor, is produced by activated macrophages in the form of pro-protein and belongs to the interleukin-1 cytokine family (18). IL-1β is a crucial mediator of inflammatory reactions and takes part in various cell activities, including cell differentiation, proliferation as well as apoptosis. This study analyzed and compared the IL-1β level in the two groups and revealed a notably lower IL-1β level in the control group than that in the research group, indicating a notable increase of IL-1β in patients with COPD, which was a crucial factor leading to the occurrence and aggravation of the disease. The results are similar to the research results of Li et al. (19). In addition, according to related studies (20,21), VitD deficiency will also impact lung function. Therefore, this study also analyzed the VitD level in participants, and revealed a notably higher 25(OH)D level in the control group than that in the research group, indicating a severe decrease in VitD level in patients with COPD, which may be bound up with the fact that the damaged liver and kidney function in patients with COPD impacts the synthesis of VitD.

Currently, the severity of COPD is mainly assessed via the mMRC and CAT (22,23). In this study, the stability group got greatly lower mMRC and CAT scores than the exacerbation group. In addition, the correlation analysis of IL-1β and 25(OH)D with mMRC and CAT scores revealed positive associations of IL-1β with mMRC and CAT scores and negative associations of 25(OH)D with mMRC and CAT scores, which indicated correlations of IL-1β and VitD with the severity of patients' illness. Related studies have also revealed that VitD deficiency and up-regulation of IL-1β expression are bound up with the development and progression of COPD and will damage the lung function of patients (24,25), which is similar to the results of this study. Finally, this study analyzed the ROC curves of IL-1β and VitD. According to ROC curve-based analysis, IL-1β and 25(OH)D had AUCs of 0.814 and 0.583, respectively, in diagnosing AECOPD, and had specificities of 74.29% and 74.29%, respectively, in it. The results imply that IL-1β and VitD can be adopted as reference indexes for the diagnosis and treatment of COPD.

This study has determined the diagnostic value of IL-1β and VitD and their correlations with mMRC and CAT scores. However, it still has some limitations. The sample size collected in this study is limited, so the samples are not uniform like that in the randomized controlled experiment. Therefore, we hope to carry out more experiments in the follow-up research to improve the research conclusions.

Table 3. Clinical diagnostic value of IL-1β and 25(OH)D for AECOPD.

<table>
<thead>
<tr>
<th>Factors</th>
<th>IL-1β</th>
<th>25(OH)D</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC</td>
<td>0.814</td>
<td>0.583</td>
</tr>
<tr>
<td>Confidence interval</td>
<td>0.708-0.919</td>
<td>0.441-0.725</td>
</tr>
<tr>
<td>Specificity</td>
<td>56.67</td>
<td>43.33</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>97.14</td>
<td>74.29</td>
</tr>
<tr>
<td>Youden index</td>
<td>53.81</td>
<td>17.62</td>
</tr>
<tr>
<td>Cut-off</td>
<td>&gt;0.070</td>
<td>&gt;17.92</td>
</tr>
</tbody>
</table>

Figure 4. Correlations of IL-1β and 25(OH)D with mMRC and CAT scores. A. Correlation of IL-1β with mMRC score, B. Correlation of IL-1β with CAT score, C. Correlation of 25(OH)D with mMRC score, D. Correlation of 25(OH)D with CAT score.

Figure 5. ROC curves of IL-1β and 25(OH)D in the diagnosis of AECOPD.
mented during treatment, and the levels of inflammatory factors should be paid close attention to at all times. IL-1β and VitD can be regarded as novel ideas for the diagnosis and treatment of COPD, which may further improve the effect of COPD prevention and treatment.

References